We are live on ! Find out more
AMAG

AMAG Pharmaceuticals
AMAG

Delisted

AMAG was delisted on the 13th of November, 2020.

174 hedge funds and large institutions have $802M invested in AMAG Pharmaceuticals in 2017 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 74 increasing their positions, 58 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

28% more repeat investments, than reductions

Existing positions increased: 74 | Existing positions reduced: 58

6% less funds holding

Funds holding: 185174 (-11)

12% less capital invested

Capital invested by funds: $913M → $802M (-$111M)

38% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 26

70% less call options, than puts

Call options by funds: $4.04M | Put options by funds: $13.4M

Holders
174
Holders Change
-11
Holders Change %
-5.95%
% of All Funds
4.34%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
16
Increased
74
Reduced
58
Closed
26
Calls
$4.04M
Puts
$13.4M
Net Calls
-$9.37M
Net Calls Change
+$158M
Name Holding Trade Value Shares
Change
Change in
Stake
VCM
51
Voce Capital Management
California
$1.73M +$1.86M +94,109 New
VOYA Investment Management
52
VOYA Investment Management
Georgia
$1.72M +$1.56M +78,587 +531%
GCP
53
GSA Capital Partners
United Kingdom
$1.71M +$915K +46,200 +99%
SFM
54
Systematic Financial Management
New Jersey
$1.7M +$336K +16,970 +23%
SM
55
Sabby Management
Florida
$1.64M +$270K +13,615 +18%
ECM
56
EII Capital Management
New York
$1.56M +$1.68M +84,600 New
California Public Employees Retirement System
57
California Public Employees Retirement System
California
$1.52M +$35.7K +1,800 +2%
KBC Group
58
KBC Group
Belgium
$1.51M -$377K -19,039 -19%
VRS
59
Virginia Retirement Systems
Virginia
$1.44M +$834K +42,100 +116%
BCM
60
Bridgeway Capital Management
Texas
$1.39M +$287K +14,500 +24%
BNP Paribas Financial Markets
61
BNP Paribas Financial Markets
France
$1.38M +$122K +6,159 +9%
AIM
62
Alambic Investment Management
California
$1.37M +$1.48M +74,600 New
RhumbLine Advisers
63
RhumbLine Advisers
Massachusetts
$1.35M +$32.2K +1,625 +2%
CEP
64
Chicago Equity Partners
Illinois
$1.29M +$1.39M +70,180 New
Massachusetts Financial Services
65
Massachusetts Financial Services
Massachusetts
$1.29M +$40K +2,017 +3%
HP
66
Hikari Power
Japan
$1.29M +$594K +30,000 +75%
CS
67
Credit Suisse
Switzerland
$1.28M -$1.51M -75,977 -52%
Legal & General Group
68
Legal & General Group
United Kingdom
$1.25M +$128K +6,441 +10%
Credit Agricole
69
Credit Agricole
France
$1.24M -$214K -10,800 -14%
State of New Jersey Common Pension Fund D
70
State of New Jersey Common Pension Fund D
New Jersey
$1.22M
TA
71
Teachers Advisors
New York
$1.15M +$8.44K +426 +0.7%
California State Teachers Retirement System (CalSTRS)
72
California State Teachers Retirement System (CalSTRS)
California
$1.14M -$131K -6,600 -10%
Bank of America
73
Bank of America
North Carolina
$1.13M -$33.1K -1,670 -3%
AllianceBernstein
74
AllianceBernstein
Tennessee
$1.11M -$808K -40,770 -40%
UBS Group
75
UBS Group
Switzerland
$1.09M +$1.16M +58,320 +7,545%

AMAG Hedge Fund Activity: Q2 2017 in Review

174 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in AMAG Pharmaceuticals (AMAG) for Q2 2017, worth a combined $802M — down 12% from $913M a quarter earlier.

Sellers outnumbered buyers: 26 funds closed out of AMAG and 16 opened new positions — a net loss of 10 holders — while 58 trimmed existing stakes and 74 added.

The largest buyer was Camber Capital Management, opening a new position worth an estimated $33.7M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $12.6M sold.

  • 174 institutional investors held AMAG Pharmaceuticals (AMAG) as of Q2 2017, down from 185 in Q1 2017.
  • Funds reported $802M of AMAG Pharmaceuticals stock for Q2 2017, down 12% quarter-over-quarter.
  • 16 funds opened new AMAG Pharmaceuticals positions in Q2 2017 and 26 closed out, a net change of -10 holders.
  • The largest AMAG Pharmaceuticals buyer in Q2 2017 was Camber Capital Management, an estimated $33.7M added.
  • The largest AMAG Pharmaceuticals seller in Q2 2017 was Perceptive Advisors, an estimated $12.6M sold.

Based on aggregated 13F filings for Q2 2017.